Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1089199


Czech Republic Pharmaceuticals and Healthcare Report Q4 2009


Description: The Czech Republic Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the Czech Republic's pharmaceuticals and healthcare industry.

The Czech Republic has one of the most developed and technologically advanced pharmaceutical markets in Central & Eastern Europe (CEE). Despite the impact of the economic downturn, BMI believes that Czech medicine sales growth will remain healthy, if not overly impressive, over the next five years, reflecting the country’s status as one of the most mature in the region. In 2009, the drug sector is likely to contract in US dollar terms, reaching a value of US$3.74bn, although this is mainly due to exchange rate fluctuations, with BMI forecasting a 2.4% growth in real terms in local currency. Meanwhile, growth should recover in 2010 and we forecast a compound annual growth rate (CAGR) of 5.3% in local currency from 2008-2013, with the market reaching US$5bn.

According to the latest data from the Institute for Health Information and Statistics (UZIS), healthcare spending reached CZK259bn (US$15.2bn) in 2008, representing 7% of GDP. Growth has been rapid in recent years with health expenditure standing at just CZK209bn (US$11.7bn) in 2004. Yet, the burden on the state seems to be decreasing. In 2008, total out-of pocket expenditure on healthcare reached CZK40bn, representing around 15% of total health spending. Of this, the controversial fees for hospital stays, doctor consultations, and prescriptions accounted for CZK5bn (US$279mn).

However, the future of health fees – which were introduced in January 2008 – remains in doubt as the outcome of the upcoming Czech parliamentary elections is expected to be exceptionally close. BMI believes that the likely lack of a clear parliamentary majority will significantly limit the power of both parties to drive forward an ambitious policy agenda, whether that be the social protective agenda of the CSSD or the fiscal austerity and market reform agenda of the ODS. This could result in neither side having the support to enact wide-reaching health reforms.

In company terms the most significant news in the quarter was Swiss drugmaker Nycomed’s purchase of the marketing rights for 20 branded generic products from Sanofi-Aventis and Zentiva – across a number of countries in CEE – in an effort to strengthen its position in the region. The portfolio additions, which will be marketed by Nycomed in the Czech Republic, Slovakia, Romania, Hungary, Estonia and Bulgaria, should generate annual turnover of approximately EUR17mn (US$24mn). Meanwhile, pharma major GlaxoSmithKline (GSK) has displayed strong growth in the Czech Republic recently, driven by sales of vaccines such as Cervarix, which prevents cervical cancer. This performance should continue in 2009, with the Czech government announcing that it will buy 1mn doses of swine flu vaccine from the British drugmaker, with delivery beginning in September 2009.

The Czech Republic has maintained 2nd place in BMI’s Business Environment Ratings for CEE, as a result of the relatively large size of the drug market and the high per capita spend. However, deficiencies in the country’s intellectual property (IP) regulations remain a major drawback.


Contents: EXECUTIVE SUMMARY

SWOT ANALYSIS
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT

PHARMACEUTICAL BUSINESS ENVIRONMENT RATINGS
CEE Pharmaceutical Business Environment Ratings, Q409
Limits To Potential Returns
Risks to Realisation of Returns

MARKET SUMMARY

REGULATORY REGIME
Intellectual Property Environment
Pricing And Reimbursement Issues
Prescribing Rules
Distance Selling
Healthcare Sector
Hospital Sector
Opposition to Health Fees

INDUSTRY FORECAST SCENARIO
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2004-2013
Key Growth Factors – Industry
Table: Czech Republic’s Health Expenditure Indicators, 2006-2013

MACROECONOMIC OUTLOOK
Czech Republic - Economic Activity, 2006-2013
Prescription Drug Market Forecast
Table: Czech Republic – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise indicated)
Patented Product Market Forecast
Table: Patented Drugs Market Indicators, 2004-2013
Generic Drug Market Forecasts
Table: Czech Republic’s Generics Market Forecast 2004-2013
OTC Medicine Market Forecast
Table: OTC Drugs Market Indicators, 2004-2013 (US$mn unless otherwise stated)
Medical Device Market Forecast
Czech Republic Medical Device Market Forecast
Pharmaceutical Trade Forecasts
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators, 2004-2013
Key Risks to BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE
Recent Company Developments
Research And Development Sector
Wholesale
Retail Sector

COMPANY MONITOR
Multinational Companies
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Walmark
Zentiva (incorporating Sicomed)

COUNTRY SNAPSHOT: CZECH REPUBLIC DEMOGRAPHIC DATA
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012

BMI METHODOLOGY
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Sanofi-Aventis - Walmark - Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1089199

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 05:30:20
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q4 2009
Web Address:
http://www.researchandmarkets.com/reports/1089199
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 05:30:20

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)